Case Based Roundtable Logo

This roundtable series looks at combination treatments in the unresectable or metastatic bladder cancer population, as discussed by key opinion leaders at virtual live events and interviews.

Patients With Advanced Bladder Cancer Given Combination Therapies

IO Trials Change Practice in Localized and Metastatic Bladder Cancer
IO Trials Change Practice in Localized and Metastatic Bladder Cancer
December 18, 2024
Petros Grivas, MD, PhD, discusses the key trials of bladder cancer using immunotherapy he highlighted during a Case-Based Roundtable event.
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer
November 22, 2024
Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Differing Trial Designs for Immunotherapy in MIBC Yield Favorable Outcomes
Differing Trial Designs for Immunotherapy in MIBC Yield Favorable Outcomes
October 30, 2024
Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.
Opinions on Treatment Split for Prominent Questions in Bladder Cancer
Opinions on Treatment Split for Prominent Questions in Bladder Cancer
October 22, 2024
Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.
Surprising Findings With Nivolumab in Bladder Cancer Trials
Surprising Findings With Nivolumab in Bladder Cancer Trials
September 18, 2024
Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder cancer compared with trials of similar agents.
Nivolumab Shows Improved DFS in ITT and PD-L1–High Bladder Cancer
Nivolumab Shows Improved DFS in ITT and PD-L1–High Bladder Cancer
August 13, 2024
Matthew Galsky, MD, discusses the disease-free survival of nivolumab vs placebo in patients with high-risk muscle-invasive bladder cancer.